Drought is a major environmental constraint that negatively affects crop germination, seedling establishment, and overall yield. This study presents a sustainable approach to improving wheat productivity under water-deficit conditions through the application of a gellan gum-based hydrogel enriched with the growth stimulant. The hydrogel was synthesized by inducing ionic gelation of gellan gum using potassium chloride and ammonium sulfate, forming a robust, cross-linked polymer network. Wheat seeds were coated with one to eight layers of the hydrogel using a sequential dipping and drying process. Optimal seedling performance was achieved with a two-layer coating, balancing sufficient water retention with adequate gas exchange. FTIR spectroscopy and pH analysis confirmed ionic interactions between Kaz-6 and the carboxyl groups of gellan, supporting its stable incorporation within the polymer matrix. Mechanical characterization showed that ammonium sulfate significantly enhanced gel strength and cross-linking density compared to potassium chloride. Laboratory germination assays and greenhouse trials demonstrated that seeds coated with gellan hydrogel containing Kaz-6 showed enhanced germination rates, greater biomass accumulation, and significantly improved drought tolerance—surviving up to 10 days longer than controls under water-limited conditions. These findings highlight the potential of biopolymer-based hydrogels as eco-friendly seed coating materials that can improve crop resilience and productivity in arid environments. The proposed formulation aligns with sustainable agriculture goals and represents a promising direction for future field-scale applications in climate-adaptive farming systems.

Acute pneumonia is frequently accompanied by immune suppression, particularly affecting T-cell subsets, such as CD4⁺, CD4⁺CD25⁺, and CD4⁺CD25⁺FoxP3⁺, which are critical for immune regulation. This study evaluates the immunomodulatory potential of a novel fluorinated piperazine-based aminophosphonate, complexed with β-cyclodextrin ((o-Fph)PPhβCD), comparing it with the clinically approved agent Polyoxidonium (PO) in a rat model of oleic acid-induced acute pneumonia. Flow cytometric analysis revealed that (o-Fph)PPhβCD significantly restored CD4⁺ and CD4⁺CD25⁺ T-cell levels and induced a sustained reduction in regulatory CD4⁺CD25⁺FoxP3⁺ cells, suggesting enhanced effector immune activity. While PO provided early immunorestorative effects, (o-Fph)PPhβCD exerted a more prolonged response, which was particularly evident by day 14. Structural confirmation of the inclusion complex was achieved through IR and NMR spectroscopy. These findings highlight (o-Fph)PPhβCD as a promising immunotherapeutic candidate that is capable of rebalancing immune cell populations and supporting host defense mechanisms during acute pulmonary inflammation.

A novel inclusion complex of a fluorinated pyrazolopiperidine derivative (5-benzyl-7-(2-fluorobenzylidene)-2,3-bis(2-fluorophenyl)-3,3a,4,5,6,7-hexahydro-2H-pyrazolo [4,3-c]pyridine hydrochloride, PP·HCl) with β-cyclodextrin (PPβCD) was designed, synthesized, and characterized as a potential therapeutic agent for chemotherapy-induced myelosuppression and lymphopenia. Encapsulation of PP within β-cyclodextrin increased aqueous solubility by approximately 3.4-fold and improved dissolution rate by 2.8-fold compared with the free compound. Structural analysis using IR, ^1H/^13C NMR, and TLC confirmed the formation of a stable 1:1 host–guest complex, and the disappearance of free PP signals further supported complete encapsulation. In vivo evaluation in a cyclophosphamide-induced myelosuppression model demonstrated that PPβCD accelerated hematopoietic recovery, restoring leukocyte and erythrocyte counts 35–40% faster than methyluracil, without any signs of systemic toxicity. These findings indicate that β-cyclodextrin complexation significantly enhances solubility, dissolution, and biological efficacy of the pyrazolopiperidine scaffold, supporting further preclinical development of PPβCD as a supportive therapy for chemotherapy-related hematological complications.